Gra zespołowa – czyli jak wykorzystać leki wieloskładnikowe i hybrydowe, aby ograniczyć ryzyko sercowo-naczyniowe Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2020
Słowa kluczowe:
nadciśnienie tętnicze, hipercholesterolemia, leczenie, pojedyncza tabletka hybrydowa
##plugins.themes.bootstrap3.article.main##
Abstrakt
Możliwości prewencji, zarówno pierwotnej, jak i wtórnej, daleko przekraczają korzyści jakiejkolwiek terapii ostrych stanów kardiologicznych. Praca zarysowuje podstawowe problemy we wdrażaniu w codziennej praktyce ustalonych, skutecznych metod postępowania w zakresie ograniczania ryzyka sercowo-naczyniowego. Wskazano w niej zasadnicze bariery słabego wdrażania wybranych zaleceń i możliwości wykorzystania terapii lekami złożonymi lub hybrydowymi w celu skuteczniejszej kontroli czynników ryzyka, a także podkreślono możliwe korzyści szerokiego stosowania takich leków w codziennej praktyce.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Waliczek , M., & Rozentryt, P. (2020). Gra zespołowa – czyli jak wykorzystać leki wieloskładnikowe i hybrydowe, aby ograniczyć ryzyko sercowo-naczyniowe. Medycyna Faktów , 13(4(49), 476-481. https://doi.org/10.24292/01.MF.0420.14
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Bandosz P, O’Flaherty M, Drygas W et al. Decline in mortality from coronary heart disease in Poland after socioeconomic transformation: modelling study. BMJ (Clinical research ed). 2012; 344: d8136.
2. Ford ES, Ajani UA, Croft JB et al. Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000. N Engl J Med. 2007; 356(23): 2388-98.
3. Pajak A, Szafraniec K, Polak M et al. Changes in the prevalence, treatment, and control of hypercholesterolemia and other dyslipidemias over 10 years in Poland: the WOBASZ study. Pol Arch Med Wewn. 2016; 126(9): 642-52.
4. Małyszko J, Mastej M, Banach M et al. Do we know more about hypertension in Poland after the May Measurement Month 2017? Europe. Eur Heart J Suppl. 2019; 21(suppl D): D97-D100.
5. Zdrojewski T, Solnica B, Cybulska B et al. Prevalence of lipid abnormalities in Poland. The NATPOL 2011 survey. Kardiol Pol. 2016; 74(3): 213-23.
6. Pająk A, Szafraniec K, Polak M et al. Changes in the prevalence, treatment, and control of hypercholesterolemia and other dyslipidemias over 10 years in Poland: the WOBASZ study. Polskie Archiwum Medycyny Wewnetrznej. 2016; 126(9): 642-52.
7. Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2019; 41(1): 111-88.
8. Niklas A, Flotyńska A, Puch-Walczak A et al. Prevalence, awareness, treatment and control of hypertension in the adult Polish population – Multi-center National Population Health Examination Surveys – WOBASZ studies. Arch Med Sci. 2018; 14(5): 951-61.
9. Kearney PM, Whelton M, Reynolds K et al. Global burden of hypertension: analysis of worldwide data. Lancet (London, England). 2005; 365(9455): 217-23.
10. Fuchs FD, Whelton PK. High Blood Pressure and Cardiovascular Disease. Hypertension. 2020; 75(2): 285-92.
11. Ference BA, Ginsberg HN, Graham I et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; 38(32): 2459-72.
12. Silverman MG, Ference BA, Im K et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA. 2016; 316(12): 1289-97.
13. Ettehad D, Emdin CA, Kiran A et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta- analysis. Lancet (London, England). 2016; 387(10022): 957-67.
14. Ference BA, Yoo W, Alesh I et al. Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease: A Mendelian Randomization Analysis. J Am Coll Cardiol. 2012; 60(25): 2631-9.
15. Ference BA, Bhatt DL, Catapano AL et al. Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. JAMA. 2019; 322(14): 1381-91.
16. Niklas A, Marcinkowska J, Kozela M et al. Blood pressure and cholesterol control in patients with hypertension and hypercholesterolemia: the results from the Polish multicenter national health survey WOBASZ II. Pol Arch Intern Med. 2019; 129(12): 864-73.
17. Dyrbus K, Gasior M, Desperak P et al. Characteristics of lipid profile and effectiveness of management of dyslipidaemia in patients with acute coronary syndromes – Data from the TERCET registry with 19,287 patients. Pharmacol Res. 2019; 139: 460-6.
18. Buddhari W, Uerojanaungkul P, Sriratanasathavorn C et al. Low-Density Lipoprotein Cholesterol Target Attainment in Patients Surviving an Acute Coronary Syndrome in Thailand: Results From the Dyslipidaemia International Study (DYSIS) II. Heart Lung Circ. 2020; 29(3): 405-13.
19. Chapman RH, Benner JS, Petrilla AA et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005; 165(10): 1147-52.
20. Ward NC, Watts GF, Eckel RH. Statin Toxicity. Circ Res. 2019; 124(2): 328-50.
21. Banach M, Rizzo M, Toth PP, et al. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci. 2015; 11(1): 1-23.
22. Soran H, France M, Adam S et al. Quantitative evaluation of statin effectiveness versus intolerance and strategies for management of intolerance. Atherosclerosis. 2020; 306: 33-40.
23. Nielsen SF, Nordestgaard BG. Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. Eur Heart J. 2015; 37(11): 908-16.
24. Gupta A, Thompson D, Whitehouse A et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet. 2017; 389(10088): 2473-81.
25. Burnier M, Egan BM. Adherence in Hypertension. Circ Res. 2019; 124(7): 1124-40.
26. Chowdhury R, Khan H, Heydon E et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013; 34(38): 2940-8.
27. Gupta P, Patel P, Štrauch B et al. Risk Factors for Nonadherence to Antihypertensive Treatment. Hypertension. 2017; 69(6): 1113-20.
28. Simons LA, Chung E, Ortiz M. Long-term persistence with single-pill, fixed-dose combination therapy versus two pills of amlodipine and perindopril for hypertension: Australian experience. Curr Med Res Opin. 2017; 33(10): 1783-7.
29. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018; 39(33): 3021-104.
2. Ford ES, Ajani UA, Croft JB et al. Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000. N Engl J Med. 2007; 356(23): 2388-98.
3. Pajak A, Szafraniec K, Polak M et al. Changes in the prevalence, treatment, and control of hypercholesterolemia and other dyslipidemias over 10 years in Poland: the WOBASZ study. Pol Arch Med Wewn. 2016; 126(9): 642-52.
4. Małyszko J, Mastej M, Banach M et al. Do we know more about hypertension in Poland after the May Measurement Month 2017? Europe. Eur Heart J Suppl. 2019; 21(suppl D): D97-D100.
5. Zdrojewski T, Solnica B, Cybulska B et al. Prevalence of lipid abnormalities in Poland. The NATPOL 2011 survey. Kardiol Pol. 2016; 74(3): 213-23.
6. Pająk A, Szafraniec K, Polak M et al. Changes in the prevalence, treatment, and control of hypercholesterolemia and other dyslipidemias over 10 years in Poland: the WOBASZ study. Polskie Archiwum Medycyny Wewnetrznej. 2016; 126(9): 642-52.
7. Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2019; 41(1): 111-88.
8. Niklas A, Flotyńska A, Puch-Walczak A et al. Prevalence, awareness, treatment and control of hypertension in the adult Polish population – Multi-center National Population Health Examination Surveys – WOBASZ studies. Arch Med Sci. 2018; 14(5): 951-61.
9. Kearney PM, Whelton M, Reynolds K et al. Global burden of hypertension: analysis of worldwide data. Lancet (London, England). 2005; 365(9455): 217-23.
10. Fuchs FD, Whelton PK. High Blood Pressure and Cardiovascular Disease. Hypertension. 2020; 75(2): 285-92.
11. Ference BA, Ginsberg HN, Graham I et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; 38(32): 2459-72.
12. Silverman MG, Ference BA, Im K et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA. 2016; 316(12): 1289-97.
13. Ettehad D, Emdin CA, Kiran A et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta- analysis. Lancet (London, England). 2016; 387(10022): 957-67.
14. Ference BA, Yoo W, Alesh I et al. Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease: A Mendelian Randomization Analysis. J Am Coll Cardiol. 2012; 60(25): 2631-9.
15. Ference BA, Bhatt DL, Catapano AL et al. Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. JAMA. 2019; 322(14): 1381-91.
16. Niklas A, Marcinkowska J, Kozela M et al. Blood pressure and cholesterol control in patients with hypertension and hypercholesterolemia: the results from the Polish multicenter national health survey WOBASZ II. Pol Arch Intern Med. 2019; 129(12): 864-73.
17. Dyrbus K, Gasior M, Desperak P et al. Characteristics of lipid profile and effectiveness of management of dyslipidaemia in patients with acute coronary syndromes – Data from the TERCET registry with 19,287 patients. Pharmacol Res. 2019; 139: 460-6.
18. Buddhari W, Uerojanaungkul P, Sriratanasathavorn C et al. Low-Density Lipoprotein Cholesterol Target Attainment in Patients Surviving an Acute Coronary Syndrome in Thailand: Results From the Dyslipidaemia International Study (DYSIS) II. Heart Lung Circ. 2020; 29(3): 405-13.
19. Chapman RH, Benner JS, Petrilla AA et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005; 165(10): 1147-52.
20. Ward NC, Watts GF, Eckel RH. Statin Toxicity. Circ Res. 2019; 124(2): 328-50.
21. Banach M, Rizzo M, Toth PP, et al. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci. 2015; 11(1): 1-23.
22. Soran H, France M, Adam S et al. Quantitative evaluation of statin effectiveness versus intolerance and strategies for management of intolerance. Atherosclerosis. 2020; 306: 33-40.
23. Nielsen SF, Nordestgaard BG. Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. Eur Heart J. 2015; 37(11): 908-16.
24. Gupta A, Thompson D, Whitehouse A et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet. 2017; 389(10088): 2473-81.
25. Burnier M, Egan BM. Adherence in Hypertension. Circ Res. 2019; 124(7): 1124-40.
26. Chowdhury R, Khan H, Heydon E et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013; 34(38): 2940-8.
27. Gupta P, Patel P, Štrauch B et al. Risk Factors for Nonadherence to Antihypertensive Treatment. Hypertension. 2017; 69(6): 1113-20.
28. Simons LA, Chung E, Ortiz M. Long-term persistence with single-pill, fixed-dose combination therapy versus two pills of amlodipine and perindopril for hypertension: Australian experience. Curr Med Res Opin. 2017; 33(10): 1783-7.
29. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018; 39(33): 3021-104.